Aditxt Inc

Aditxt, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. It has a worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that the global Phase 3 PRESECO (PREventing SEvere COVID-19) trial evaluating oral Avigan®/Reeqonus™ (favipiravir) as a potential at-home therapy for patients with mild-to-moderate COVID-19, which was being run by Appili Therapeutics, Inc. (“Appili”)(TSX: APLI), a consortium partner of AiPharma Global Holdings LLC (“AiPha

Aditxt Provides an Update Regarding its Target Acquisition AiPharma Global Holdings LLC

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX), (“Aditxt” or the “Company”) a biotechnology innovation company with a mission to improve the health of the immune system, announced today a partnership with CLX Health, a developer of cloud-based solutions. The goal of this partnership is to accelerate the market availability of AditxtScore™ for COVID-19 through CLX Health's TrustAssure Solution Suite. TrustAssure Solution Suite is a multi-stakeholder engagement platform that consumer

Aditxt Partners With CLX Health to Offer AditxtScore™ for COVID-19 Immune Monitoring Service Through CLX's TrustAssure™ Platform

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the closing of its previously announced underwritten public offering of 2,833,333 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $4.25 million, before deducting underwriting discounts and offering expenses. Aditxt plans to use a portion of the net of underwriting discounts

Aditxt Announces Closing of $4.25 Million Public Offering

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the Company's Co-Founder, Chairman, and CEO Amro Albanna will present at the Dawson James Small Cap Growth Conference on Thursday, October 21, 2021 at 2:50 p.m. ET in Jupiter, Florida. Mr. Albanna will also participate in 1x1 meetings with investors and analysts. Dawson James' flagship Small Cap Growth Co

Aditxt to Present at the Dawson James 6th Annual Small Cap Growth Conference in Florida on October 21, 2021

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the pricing of an underwritten public offering of 2,833,333 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $4.25 million, before deducting underwriting discounts and offering expenses. Aditxt plans to use a portion of the net proceeds of approximately $3.91 million from thi

Aditxt Announces Pricing of $4.25 Million Public Offering

Arbutus Biopharma

Adverum Biotechnologies

Ameri Holdings

Evofem Biosciences Inc

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the Company's Co-Founder, Chairman, and CEO Amro Albanna will present at the LD Micro Main Event in person on October 13, 2021 at 8:30 AM PT / 11:30 AM ET on Track 1. Mr. Albanna will also participate in 1x1 meetings with investors and analysts. This year's LD Micro Main Event will take place in person on

Aditxt to Present at the LD Micro Main Event in Los Angeles on October 13, 2021

The stock price of Aditxt Inc (NASDAQ: ADTX) increased by over 8% today. This is why it happened.

ADTX Stock: Why It Increased Today

Globalstar

Ring Energy

Are these penny stocks worth adding to your watchlist in 2021? The post Are Penny Stocks Worth It?

Are Penny Stocks Worth It? Here's 3 to Know About in October

Aditxt Inc (NASDAQ: ADTX) has agreed to acquire AiPharma Global Holdings LLC, focused on discovering, developing, and commercializing antiviral therapies. AiPharma Global holds exclusive rights to Avigan/Reeqonus/Qifenda and all formulations of favipiravir, a broad spectrum oral antiviral drug that targets COVID-19 and other infectious diseases.

Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate

Today, investors in Aditxt and ADTX stock are seeing impressive gains following an announced acquisition of a company with a Covid-19 drug. The post ADTX Stock: The Huge Covid-19 News Lifting Aditxt Today appeared first on InvestorPlace.

ADTX Stock: The Huge Covid-19 News Lifting Aditxt Today

Dr. Reddy's Labs

DUBAI, United Arab Emirates, Oct. 5, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases today announced it has entered a binding agreement to sell all of its assets through the sale of one of its wholly owned group subsidaries, to Aditxt Inc. (Nasdaq: ADTX). Aditxt is a biotech innovation company with a mission to improve the health of the immune system.

AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda That Has Treated Over 1.5M COVID-19 Patients Since The Outbreak.

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it has entered into a transaction agreement to reach a definitive agreement by the end of November 2021 to acquire a subsidiary (“AiPharma”) of AiPharma Global Holdings LLC (“AiPharma Global”) which is to own all of the assets of AiPharma Global, a company focused on discovering, developing and commercializing antiviral t

Aditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and Canada

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt, or the “Company”). (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been appointed as President and will work closely with the Company's CEO, Amro Albanna, to execute Aditxt's business strategy. Thomas J. Farley, who has served as Controller and Principal

Aditxt Appoints Corinne Pankovcin as President and Thomas J. Farley as Chief Financial Officer as Company Prepares for Global Commercialization

RICHMOND, Va. & LEXINGTON, Ky.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced a partnership with SphereDX, an advanced clinical diagnostic lab focusing on next-generation genomic and metabolomic clinical testing, to offer its AditxtScore™ for COVID-19. The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutral

Aditxt, Inc. and SphereDX Launch AditxtScore™ for COVID-19 in Kentucky, Ohio and Indiana to Address Individual Immune Status Uncertainty and Help Evaluate Cadence for Booster Shots

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it has closed on a registered direct offering for $11 million announced on August 26, 2021 and funded a bridge loan to its acquisition target, satisfying a key term of the Letter of Intent (LOI). Additionally, the Company entered into an agreement with the holder of its outstanding convertible note, whereby the parties agreed to wai

Aditxt Announces Closing of $11 Million Registered Direct Offering, and Funding of Bridge Loan Satisfying a Key Term of its Letter of Intent for Planned Acquisition of Commercial Stage Pharma Company with Anti-Viral COVID-19 Therapy

Investors need to pay close attention to Aditxt (ADTX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Aditxt (ADTX) Stock?

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that it has entered into definitive agreements with certain institutional investors to purchase 4,583,334 shares of its common stock at a purchase price of $2.40 per share in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $11.0 million, before payment of commissions and expe

Aditxt Announces Pricing of $11.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Today, investors in Aditxt and ADTX stock are seeing substantial gains, as the company announced a big acquisition investors seem to like. The post ADTX Stock: What Is the Huge Covid-19 News Lifting Aditxt 70% Today?

ADTX Stock: What Is the Huge Covid-19 News Lifting Aditxt 70% Today?

Vinco Ventures

Cinedigm

Which penny stocks are investors watching as AMC stock and Bitcoin climb today?` The post Best Penny Stocks to Buy Now?

Best Penny Stocks to Buy Now? 3 to Watch as AMC and Bitcoin Climb

The stock price of Aditxt Inc (NASDAQ: ADTX) increased by over 99% during intraday trading. This is why it happened.

ADTX Stock: Over 99% Increase Explanation

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced that it has signed a letter of intent ("the LOI") to acquire a biopharmaceutical company, the “Target Company”, commercializing COVID-19 antiviral oral therapy. The Target Company is currently selling its products under emergency and compassionate use, standard of care, and full approval in multiple countries internationally outside

Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced a partnership with Great Lakes Medical Laboratory, Inc. (GLML), a full-service medical reference laboratory, to offer its AditxtScore™ for COVID-19 throughout the State of Michigan. The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing anti

Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (the “Company” or “Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced its Psoriasis clinical program will now be slated for 2022 instead of December 2021 as previously announced. The updated timeline is due to a lengthier large scale clinical grade manufacturing and approval process for initiating toxicology studies. Meanwhile, Aditxt has continued to strengthen the data se

Aditxt Provides Update on AditxtReprogramming's™ Apoptotic DNA Immunotherapy Therapeutic Platform

Aditxt Inc (NASDAQ: ADTX) has announced enhancements to its AditxtScore for COVID-19 to include a high-sensitivity neutralizing antibody diagnostic. The multi-dimensional immune response test tracks multiple combinations of antibody responses against several different antigens.

News for Aditxt Inc Stock (ADTX)